TY  - GEN 
AU  - Aragón-Herrera, A.
AU  - Otero Santiago, Manuel Francisco
AU  - Anido Varela, Laura
AU  - Moraña Fernández, Sandra
AU  - Campos Toimil, Manuel
AU  - García-Caballero Parada, Tomas
AU  - Barral, L.
AU  - Tarazón, E.
AU  - Roselló-Lletí, E.
AU  - Portolés, M.
AU  - Gualillo, Oreste
AU  - Moscoso, I.
AU  - Lage Fernández, Ricardo
AU  - González Juanatey, José Ramón
AU  - Feijóo-Bandín, S.
AU  - Lago Paz, Francisca
PY  - 2022
SN  - 1663-9812
UR  - http://hdl.handle.net/20.500.11940/20429
AB  - The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes...
LA  - eng
TI  - The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
DO  - 10.3389/fphar.2022.827033
KW  - AS Santiago
KW  - CHUS
KW  - IDIS
VL  - 13
ER  -